Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease

Background Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical laboratory analysis 2023-01, Vol.37 (1), p.e24795-n/a
Hauptverfasser: Yuan, Zhong‐Wen, Gan, Hai‐Ling, Jin, Hong‐Liu, Feng, Xiao‐Ying, Wang, Ming, Zhou, Hua‐Ping, Zhang, Jing
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 1
container_start_page e24795
container_title Journal of clinical laboratory analysis
container_volume 37
creator Yuan, Zhong‐Wen
Gan, Hai‐Ling
Jin, Hong‐Liu
Feng, Xiao‐Ying
Wang, Ming
Zhou, Hua‐Ping
Zhang, Jing
description Background Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. This study aimed to establish and validate a method to quantify serum aromatic amino acid (AAA) metabolites as biomarkers of metabolic disorders in patients with HIV. Methods The AAAs and metabolites were analyzed using high‐performance liquid chromatography–tandem mass spectrometry. Pearson's correlation, heatmap, and receiver operating characteristic curve analyses were used for statistical analysis. Results Under optimal detection conditions, the lower limits of phenylalanine (Phe), tryptophan (Trp), kynurenine (Kyn), tyrosine, phenylacetylglutamine (PAGln), and 5‐hydroxytryptamine quantification reached 0.02, 0.02, 0.01, 0.02, 0.01, and 0.002 μg/ml, respectively, and the precision of intra‐ and inter‐day was stay below 10.30%. Serum samples were stable for at least 6 months when stored at −80°C. The inter‐group differences and associations between the biomarkers exhibited a particular volatility trend in PAGln, Trp, and Kyn metabolism in HIV‐infected patients with metabolic syndrome. Conclusions The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome. Acquired immunoeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. Aromatic amino acids (AAA) and metabolites mainly including tyrosine, phenylalanine (Phe), and tryptophan (Trp), kynurenine and 5‐hydroxytryptamine. In addition, the intestinal flora was able to break down Trp and Phe, and generate indole, indolic acid, skatole, tryptamine, phenylpyruvic acid, and phenyl acetic acid. Phenylacetic acid can be converted to phenyl acetylglutamine (PAGln) under the action of Gln PA‐transferase in liver, which have been confirmed closely related to cardiovascular d
doi_str_mv 10.1002/jcla.24795
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2747008313</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2763820779</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3935-e330c3418abe3c4966e1f2b483b757f5b500acb382cbb8ac6e2f5a349a1e62eb3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi1E1W5LL_wAZIkLQkrxRxI7x2pVaNFKXIBrNPaOqVdJvNhOq1747XiblgOHniy9fvTMaF5C3nJ2wRkTn3Z2gAtRq655RVacdboSWjSvyYpprSrNuDwhpyntGGO64-0xOZFt3dZKyxX5c3UHwwzZh4kGR-0tRLAZo0_ZWzpiBhMGnzEdfiGGEQ45jH4KFKzfJuonui8hTjnRe59v6fXNzxI6tI9SyHTrncNYAJoy_FpUW58QEr4hRw6GhOdP7xn58fnq-_q62nz7crO-3FRWdrKpUEpmZc01GJS27toWuROm1tKoRrnGNIyBNVILa4wG26JwDci6A46tQCPPyIfFu4_h94wp96NPFocBJgxz6oWqVbmO5LKg7_9Dd2GOU9muUG0ZwZTqCvVxoWwMKUV0_T76EeJDz1l_aKU_tNI_tlLgd0_K2Yy4_Yc-11AAvgD3fsCHF1T91_XmcpH-BRPKmN4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2763820779</pqid></control><display><type>article</type><title>Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Yuan, Zhong‐Wen ; Gan, Hai‐Ling ; Jin, Hong‐Liu ; Feng, Xiao‐Ying ; Wang, Ming ; Zhou, Hua‐Ping ; Zhang, Jing</creator><creatorcontrib>Yuan, Zhong‐Wen ; Gan, Hai‐Ling ; Jin, Hong‐Liu ; Feng, Xiao‐Ying ; Wang, Ming ; Zhou, Hua‐Ping ; Zhang, Jing</creatorcontrib><description>Background Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. This study aimed to establish and validate a method to quantify serum aromatic amino acid (AAA) metabolites as biomarkers of metabolic disorders in patients with HIV. Methods The AAAs and metabolites were analyzed using high‐performance liquid chromatography–tandem mass spectrometry. Pearson's correlation, heatmap, and receiver operating characteristic curve analyses were used for statistical analysis. Results Under optimal detection conditions, the lower limits of phenylalanine (Phe), tryptophan (Trp), kynurenine (Kyn), tyrosine, phenylacetylglutamine (PAGln), and 5‐hydroxytryptamine quantification reached 0.02, 0.02, 0.01, 0.02, 0.01, and 0.002 μg/ml, respectively, and the precision of intra‐ and inter‐day was stay below 10.30%. Serum samples were stable for at least 6 months when stored at −80°C. The inter‐group differences and associations between the biomarkers exhibited a particular volatility trend in PAGln, Trp, and Kyn metabolism in HIV‐infected patients with metabolic syndrome. Conclusions The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome. Acquired immunoeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. Aromatic amino acids (AAA) and metabolites mainly including tyrosine, phenylalanine (Phe), and tryptophan (Trp), kynurenine and 5‐hydroxytryptamine. In addition, the intestinal flora was able to break down Trp and Phe, and generate indole, indolic acid, skatole, tryptamine, phenylpyruvic acid, and phenyl acetic acid. Phenylacetic acid can be converted to phenyl acetylglutamine (PAGln) under the action of Gln PA‐transferase in liver, which have been confirmed closely related to cardiovascular disease. This study also attempts to explore the level changes of AAA metabolic, especially PAGln. This study aimed to establish and validate a method to quantify serum AAA metabolites as biomarkers of metabolic disorders in patients with HIV. The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome.</description><identifier>ISSN: 0887-8013</identifier><identifier>EISSN: 1098-2825</identifier><identifier>DOI: 10.1002/jcla.24795</identifier><identifier>PMID: 36464783</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Acquired immune deficiency syndrome ; AIDS ; Amino acids ; Amino Acids, Aromatic ; Antiretroviral therapy ; aromatic amino acid metabolites ; Biomarkers ; Body mass index ; Diabetes ; High-performance liquid chromatography ; high‐performance liquid chromatography–tandem mass spectrometry ; HIV ; HIV Infections ; Human immunodeficiency virus ; Humans ; Infections ; Infectious diseases ; Insulin resistance ; Lipids ; Mass spectroscopy ; metabolic disorder ; Metabolic disorders ; Metabolic Syndrome ; Metabolites ; Microbiota ; phenylacetylglutamine ; Phenylalanine ; Statistical analysis ; Tandem Mass Spectrometry - methods ; Tryptophan ; Tyrosine</subject><ispartof>Journal of clinical laboratory analysis, 2023-01, Vol.37 (1), p.e24795-n/a</ispartof><rights>2022 The Authors. published by Wiley Periodicals LLC.</rights><rights>2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.</rights><rights>2023. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3935-e330c3418abe3c4966e1f2b483b757f5b500acb382cbb8ac6e2f5a349a1e62eb3</citedby><cites>FETCH-LOGICAL-c3935-e330c3418abe3c4966e1f2b483b757f5b500acb382cbb8ac6e2f5a349a1e62eb3</cites><orcidid>0000-0003-3443-4723</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcla.24795$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcla.24795$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,860,1411,11541,27901,27902,45550,45551,46027,46451</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36464783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yuan, Zhong‐Wen</creatorcontrib><creatorcontrib>Gan, Hai‐Ling</creatorcontrib><creatorcontrib>Jin, Hong‐Liu</creatorcontrib><creatorcontrib>Feng, Xiao‐Ying</creatorcontrib><creatorcontrib>Wang, Ming</creatorcontrib><creatorcontrib>Zhou, Hua‐Ping</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><title>Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease</title><title>Journal of clinical laboratory analysis</title><addtitle>J Clin Lab Anal</addtitle><description>Background Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. This study aimed to establish and validate a method to quantify serum aromatic amino acid (AAA) metabolites as biomarkers of metabolic disorders in patients with HIV. Methods The AAAs and metabolites were analyzed using high‐performance liquid chromatography–tandem mass spectrometry. Pearson's correlation, heatmap, and receiver operating characteristic curve analyses were used for statistical analysis. Results Under optimal detection conditions, the lower limits of phenylalanine (Phe), tryptophan (Trp), kynurenine (Kyn), tyrosine, phenylacetylglutamine (PAGln), and 5‐hydroxytryptamine quantification reached 0.02, 0.02, 0.01, 0.02, 0.01, and 0.002 μg/ml, respectively, and the precision of intra‐ and inter‐day was stay below 10.30%. Serum samples were stable for at least 6 months when stored at −80°C. The inter‐group differences and associations between the biomarkers exhibited a particular volatility trend in PAGln, Trp, and Kyn metabolism in HIV‐infected patients with metabolic syndrome. Conclusions The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome. Acquired immunoeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. Aromatic amino acids (AAA) and metabolites mainly including tyrosine, phenylalanine (Phe), and tryptophan (Trp), kynurenine and 5‐hydroxytryptamine. In addition, the intestinal flora was able to break down Trp and Phe, and generate indole, indolic acid, skatole, tryptamine, phenylpyruvic acid, and phenyl acetic acid. Phenylacetic acid can be converted to phenyl acetylglutamine (PAGln) under the action of Gln PA‐transferase in liver, which have been confirmed closely related to cardiovascular disease. This study also attempts to explore the level changes of AAA metabolic, especially PAGln. This study aimed to establish and validate a method to quantify serum AAA metabolites as biomarkers of metabolic disorders in patients with HIV. The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome.</description><subject>Acquired immune deficiency syndrome</subject><subject>AIDS</subject><subject>Amino acids</subject><subject>Amino Acids, Aromatic</subject><subject>Antiretroviral therapy</subject><subject>aromatic amino acid metabolites</subject><subject>Biomarkers</subject><subject>Body mass index</subject><subject>Diabetes</subject><subject>High-performance liquid chromatography</subject><subject>high‐performance liquid chromatography–tandem mass spectrometry</subject><subject>HIV</subject><subject>HIV Infections</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Insulin resistance</subject><subject>Lipids</subject><subject>Mass spectroscopy</subject><subject>metabolic disorder</subject><subject>Metabolic disorders</subject><subject>Metabolic Syndrome</subject><subject>Metabolites</subject><subject>Microbiota</subject><subject>phenylacetylglutamine</subject><subject>Phenylalanine</subject><subject>Statistical analysis</subject><subject>Tandem Mass Spectrometry - methods</subject><subject>Tryptophan</subject><subject>Tyrosine</subject><issn>0887-8013</issn><issn>1098-2825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU1v1DAQhi1E1W5LL_wAZIkLQkrxRxI7x2pVaNFKXIBrNPaOqVdJvNhOq1747XiblgOHniy9fvTMaF5C3nJ2wRkTn3Z2gAtRq655RVacdboSWjSvyYpprSrNuDwhpyntGGO64-0xOZFt3dZKyxX5c3UHwwzZh4kGR-0tRLAZo0_ZWzpiBhMGnzEdfiGGEQ45jH4KFKzfJuonui8hTjnRe59v6fXNzxI6tI9SyHTrncNYAJoy_FpUW58QEr4hRw6GhOdP7xn58fnq-_q62nz7crO-3FRWdrKpUEpmZc01GJS27toWuROm1tKoRrnGNIyBNVILa4wG26JwDci6A46tQCPPyIfFu4_h94wp96NPFocBJgxz6oWqVbmO5LKg7_9Dd2GOU9muUG0ZwZTqCvVxoWwMKUV0_T76EeJDz1l_aKU_tNI_tlLgd0_K2Yy4_Yc-11AAvgD3fsCHF1T91_XmcpH-BRPKmN4</recordid><startdate>202301</startdate><enddate>202301</enddate><creator>Yuan, Zhong‐Wen</creator><creator>Gan, Hai‐Ling</creator><creator>Jin, Hong‐Liu</creator><creator>Feng, Xiao‐Ying</creator><creator>Wang, Ming</creator><creator>Zhou, Hua‐Ping</creator><creator>Zhang, Jing</creator><general>John Wiley &amp; Sons, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3443-4723</orcidid></search><sort><creationdate>202301</creationdate><title>Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease</title><author>Yuan, Zhong‐Wen ; Gan, Hai‐Ling ; Jin, Hong‐Liu ; Feng, Xiao‐Ying ; Wang, Ming ; Zhou, Hua‐Ping ; Zhang, Jing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3935-e330c3418abe3c4966e1f2b483b757f5b500acb382cbb8ac6e2f5a349a1e62eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>AIDS</topic><topic>Amino acids</topic><topic>Amino Acids, Aromatic</topic><topic>Antiretroviral therapy</topic><topic>aromatic amino acid metabolites</topic><topic>Biomarkers</topic><topic>Body mass index</topic><topic>Diabetes</topic><topic>High-performance liquid chromatography</topic><topic>high‐performance liquid chromatography–tandem mass spectrometry</topic><topic>HIV</topic><topic>HIV Infections</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Insulin resistance</topic><topic>Lipids</topic><topic>Mass spectroscopy</topic><topic>metabolic disorder</topic><topic>Metabolic disorders</topic><topic>Metabolic Syndrome</topic><topic>Metabolites</topic><topic>Microbiota</topic><topic>phenylacetylglutamine</topic><topic>Phenylalanine</topic><topic>Statistical analysis</topic><topic>Tandem Mass Spectrometry - methods</topic><topic>Tryptophan</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yuan, Zhong‐Wen</creatorcontrib><creatorcontrib>Gan, Hai‐Ling</creatorcontrib><creatorcontrib>Jin, Hong‐Liu</creatorcontrib><creatorcontrib>Feng, Xiao‐Ying</creatorcontrib><creatorcontrib>Wang, Ming</creatorcontrib><creatorcontrib>Zhou, Hua‐Ping</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical laboratory analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yuan, Zhong‐Wen</au><au>Gan, Hai‐Ling</au><au>Jin, Hong‐Liu</au><au>Feng, Xiao‐Ying</au><au>Wang, Ming</au><au>Zhou, Hua‐Ping</au><au>Zhang, Jing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease</atitle><jtitle>Journal of clinical laboratory analysis</jtitle><addtitle>J Clin Lab Anal</addtitle><date>2023-01</date><risdate>2023</risdate><volume>37</volume><issue>1</issue><spage>e24795</spage><epage>n/a</epage><pages>e24795-n/a</pages><issn>0887-8013</issn><eissn>1098-2825</eissn><abstract>Background Acquired immune deficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. This study aimed to establish and validate a method to quantify serum aromatic amino acid (AAA) metabolites as biomarkers of metabolic disorders in patients with HIV. Methods The AAAs and metabolites were analyzed using high‐performance liquid chromatography–tandem mass spectrometry. Pearson's correlation, heatmap, and receiver operating characteristic curve analyses were used for statistical analysis. Results Under optimal detection conditions, the lower limits of phenylalanine (Phe), tryptophan (Trp), kynurenine (Kyn), tyrosine, phenylacetylglutamine (PAGln), and 5‐hydroxytryptamine quantification reached 0.02, 0.02, 0.01, 0.02, 0.01, and 0.002 μg/ml, respectively, and the precision of intra‐ and inter‐day was stay below 10.30%. Serum samples were stable for at least 6 months when stored at −80°C. The inter‐group differences and associations between the biomarkers exhibited a particular volatility trend in PAGln, Trp, and Kyn metabolism in HIV‐infected patients with metabolic syndrome. Conclusions The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome. Acquired immunoeficiency syndrome (AIDS), human immunodeficiency virus (HIV) infection, and antiretroviral therapy are usually associated with metabolic disorders. Screening for biomarkers to evaluate the progression of metabolic disorders is important for the diagnosis and treatment of HIV infection. Aromatic amino acids (AAA) and metabolites mainly including tyrosine, phenylalanine (Phe), and tryptophan (Trp), kynurenine and 5‐hydroxytryptamine. In addition, the intestinal flora was able to break down Trp and Phe, and generate indole, indolic acid, skatole, tryptamine, phenylpyruvic acid, and phenyl acetic acid. Phenylacetic acid can be converted to phenyl acetylglutamine (PAGln) under the action of Gln PA‐transferase in liver, which have been confirmed closely related to cardiovascular disease. This study also attempts to explore the level changes of AAA metabolic, especially PAGln. This study aimed to establish and validate a method to quantify serum AAA metabolites as biomarkers of metabolic disorders in patients with HIV. The developed method can be used for rapid and sensitive quantification of the AAA metabolism profile in vivo to further appraise the process of HIV infection, evaluate intervening measures, conduct mechanistic investigations, and further study the utility of PAGln, a characteristic metabolite of AAA, as a biomarker of HIV infection coupled with metabolic syndrome.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>36464783</pmid><doi>10.1002/jcla.24795</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0003-3443-4723</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0887-8013
ispartof Journal of clinical laboratory analysis, 2023-01, Vol.37 (1), p.e24795-n/a
issn 0887-8013
1098-2825
language eng
recordid cdi_proquest_miscellaneous_2747008313
source MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Acquired immune deficiency syndrome
AIDS
Amino acids
Amino Acids, Aromatic
Antiretroviral therapy
aromatic amino acid metabolites
Biomarkers
Body mass index
Diabetes
High-performance liquid chromatography
high‐performance liquid chromatography–tandem mass spectrometry
HIV
HIV Infections
Human immunodeficiency virus
Humans
Infections
Infectious diseases
Insulin resistance
Lipids
Mass spectroscopy
metabolic disorder
Metabolic disorders
Metabolic Syndrome
Metabolites
Microbiota
phenylacetylglutamine
Phenylalanine
Statistical analysis
Tandem Mass Spectrometry - methods
Tryptophan
Tyrosine
title Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T13%3A03%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20characteristic%20metabolites%20of%20aromatic%20amino%20acids%20in%20patients%20with%20HIV%20infection%20at%20different%20stages%20of%20disease&rft.jtitle=Journal%20of%20clinical%20laboratory%20analysis&rft.au=Yuan,%20Zhong%E2%80%90Wen&rft.date=2023-01&rft.volume=37&rft.issue=1&rft.spage=e24795&rft.epage=n/a&rft.pages=e24795-n/a&rft.issn=0887-8013&rft.eissn=1098-2825&rft_id=info:doi/10.1002/jcla.24795&rft_dat=%3Cproquest_cross%3E2763820779%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2763820779&rft_id=info:pmid/36464783&rfr_iscdi=true